CVRx (CVRX) Net Income towards Common Stockholders (2020 - 2026)
CVRx (CVRX) recorded quarterly Net Income towards Common Stockholders of -$13.1 million in Q1 2026, down 9.77% quarter-over-quarter from -$12.0 million in Q4 2025, and up 4.69% on a YoY basis from -$12.5 million in Q1 2025.
CVRx (CVRX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
CVRx's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$13.1 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 4.69% year-over-year to -$13.1 million; the TTM figure through Mar 2026 stood at -$52.7 million (down 2.2% YoY), while the FY2025 annual figure was -$53.3 million, up 11.07% from the prior year.
- Net Income towards Common Stockholders was -$13.1 million for Q1 2026 at CVRx, down from -$12.0 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$9.0 million in Q3 2023 to a low of -$22.2 million in Q1 2024.
- Historically, Net Income towards Common Stockholders has averaged -$12.3 million across 5 years, with a median of -$11.7 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders plunged 95.06% in 2024, then soared 37.95% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$10.5 million in 2022, then rose by 14.43% to -$9.0 million in 2023, then retreated by 18.13% to -$10.7 million in 2024, then slipped by 12.21% to -$12.0 million in 2025, then declined by 9.77% to -$13.1 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$13.1 million (Q1 2026), -$12.0 million (Q4 2025), and -$12.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 199.50 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | CVRx | 132.04 Mn | 59.74 Mn | 12.88 Mn | -13.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.12 Mn |
| Dec 31, 2025 | -11.95 Mn |
| Sep 30, 2025 | -12.87 Mn |
| Jun 30, 2025 | -14.74 Mn |
| Mar 31, 2025 | -13.77 Mn |
| Dec 31, 2024 | -10.65 Mn |
| Sep 30, 2024 | -13.10 Mn |
| Jun 30, 2024 | -14.03 Mn |
| Mar 31, 2024 | -22.19 Mn |
| Dec 31, 2023 | -9.02 Mn |
| Sep 30, 2023 | -9.01 Mn |
| Jun 30, 2023 | -11.65 Mn |
| Mar 31, 2023 | -11.37 Mn |
| Dec 31, 2022 | -10.54 Mn |
| Sep 30, 2022 | -9.83 Mn |
| Jun 30, 2022 | -11.07 Mn |
| Mar 31, 2022 | -9.99 Mn |
| Dec 31, 2021 | -10.57 Mn |
| Sep 30, 2021 | -6.13 Mn |
| Jun 30, 2021 | -17.75 Mn |